Newsroom
201 Therapeutics receives CHF 40,000 from Venture Kick to advance liver cancer therapy commercialization
26.05.2026
201 Therapeutics receives CHF 40,000 from Venture Kick to advance its oral small-molecule therapies for hepatocellular carcinoma. ... more
Biodelphis Therapeutics receives CHF 150,000 from Venture Kick to advance targeted therapies for difficult-to-treat cancers
22.05.2026
The EPFL spin-off Biodelphis Therapeutics has obtained CHF 150,000 from Venture Kick to develop a new generation of targeted thera ... more
HAYA Therapeutics starts clinical trial for heart disease therapy
20.05.2026
Swiss biotech company HAYA Therapeutics has reached a new milestone as it officially entered the clinical stage with the dosing of ... more
Newsletter Archive
Spring momentum across Swiss startups 🌱
A record 2025, and kicking bigger in 2026! 🚀
Kicking Finish, Bold Outlook✨
Press releases
Press review
1000 Unternehmen mit Venture Kick gegründet
Media contacts
For media enquiries, please email our communications team. If you have a general question about Venture Kick please visit our about us page.
Learn more about Venture Kick or download the latest annual report for detailed information.
